Ian Mortimer

Ian Mortimer is the President and CEO of Xenon Pharmaceuticals. Ian has over 25 years of experience in the pharmaceutical industry, including finance, business development, and operations.

Mortimer began their career at Inex Pharmaceuticals in December 2004 as Chief Financial Officer. Ian then moved to Arbutus Biopharma Corporation in April 2007, where they served as Chief Financial Officer for six years. In October 2013, they joined Xenon Pharmaceuticals Inc. as Chief Financial Officer. Ian was promoted to Chief Financial Officer & Chief Operating Officer in March 2015, and then to President & CEO in June 2021.

Under Mortimer’s leadership, Xenon has grown from a small Canadian biotech company to a global leader in the development of innovative treatments for rare diseases. The company’s success is due in part to Mortimer’s financial acumen and ability to identify and capitalize on new business opportunities. Ian has a proven track record of creating shareholder value and is passionate about improving the lives of patients with rare diseases.

Some individuals on their team include Robin Sherrington - EVP, Strategy & Innovation, Sheila Grant - SVP, R&D Operations, and James Empfield - SVP, Drug Discovery.